Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amphastar Pharmaceuticals, Inc.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with documented asthma, requiring inhaled epinephrine or beta 2-agonist treatment.
No significant changes in asthma therapy and no asthma-related hospitalization or emergency visits, within 4 weeks prior to Screening
Can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout period.
Demonstrating a Screening Baseline FEV1 that is 50 - 90% of predicted normal value.
Demonstrating at least a 12% Airway Reversibility.
Demonstrating satisfactory techniques in the use of metered-dose inhaler and a hand held peak expiratory flow meter.
Female patients of child-bearing potential must be non-pregnant and non-lactating at Screening and throughout the study, and must use an acceptable method of contraception during the study.
You may not be if
A smoking history of 10-pack years, or having smoked within 12 months of screening.
Any current or past medical conditions that, per investigator discretion, might significantly affect responses to the study drugs, other than asthma.
Concurrent clinically significant diseases.
Known intolerance or hypersensitivity to any component of the study drugs.
Recent infection of the respiratory tract, before screening.
Use of prohibited medications.
Having been on other investigational drug/device studies in the last 30 days prior to screening.
Known or highly suspected substance abuse.
Clareo Health | Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
